All Stories

  1. Metabolic syndrome is associated with similar long-term prognosis in non-obese and obese patients. An analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 cohort studies
  2. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
  3. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
  4. Which Statin is Best for the Kidneys?
  5. Abstracts of the 18th Congress of the European Geriatric Medicine Society
  6. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  7. Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
  8. Anticoagulation in older people with atrial fibrillation moving to care homes: a data linkage study
  9. 2022: The Year in Cardiovascular Disease – The Year of Upfront Lipid Lowering Combination Therapy.
  10. Adherence to statin therapy - it seems we know everything, yet we do nothing…
  11. Individualized therapy in statin intolerance: the key to success
  12. Factors associated with prescription of oral anticoagulation for atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  13. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  14. Selected Abstracts from Pharmacology 2022
  15. Risk factors for post sternotomy wound complications across the patient journey: A systematised review of the literature
  16. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel
  17. P17-04 An automated tool for selection of chemical analogues to facilitate development of new physiologically-based kinetic models using a read-across approach
  18. Integrated care for atrial fibrillation management: The role of the pharmacist
  19. 1300 Transfer of outpatient paediatric prescriptions to primary care via the Electronic Prescription Service (EPS)- community pharmacist views
  20. Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review
  21. Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?
  22. Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF): A Mixed Methods Feasibility Study Protocol
  23. Lifetime serum concentration of 25-hydroxyvitamin D 25(OH) is associated with hand grip strengths: insight from a Mendelian randomisation
  24. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
  25. Prevalence of statin intolerance: a meta-analysis
  26. Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition
  27. Warfarin—Is Self-Care the Best Care?
  28. Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress
  29. Stop and Go: Barriers and Facilitators to Care Home Research
  30. Long-COVID-19: Definition, Epidemiology, and Clinical Implications
  31. CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities
  32. Potential Benefits of Phytochemicals for Abdominal Aortic Aneurysm
  33. The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study
  34. A Systematic Review of Published Physiologically based Kinetic Models and an Assessment of their Chemical Space Coverage
  35. Extreme cardiovascular risk—do we need a new risk category?
  36. Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study
  37. The management of asthma in adult patients in the community pharmacy setting: Literature review
  38. Associations between serum triglycerides and abdominal aortic calcification in a cross-sectional study from the United States of America
  39. Association between ankle-brachial index and cardiovascular mortality in a cohort from the United States of America
  40. The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4,143,517 patients
  41. Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study
  42. Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland
  43. Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective
  44. Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta‐analysis of randomized controlled trials
  45. RNA Silencing in the Management of Dyslipidemias
  46. Bacterial lipopolysaccharide–Stoking the fire of residual risk?
  47. Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry
  48. The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis
  49. Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice
  50. Statins as anti-pyroptotic agents
  51. Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia
  52. Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors - analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies.
  53. Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations
  54. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP)
  55. Assessment of asthma management in adult patients: A retrospective case-note review in a general practice
  56. Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies
  57. Exploring pharmacists’ views surrounding conscientious objection to abortion and implications in practice
  58. Prevalence of anti-nuclear autoantibodies (ANA) in the general Polish population - analysis of the influence of sex and age on the variability of ANA.
  59. Effects of statins on myocarditis: A review of underlying molecular mechanisms
  60. OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
  61. Drucebo effect – the challenge we should all definitely face!
  62. Lipid-lowering therapies: Better together
  63. OUP accepted manuscript
  64. Recent advancements in liposome-based strategies for effective drug delivery to the brain
  65. Management of Statin Intolerance
  66. Statins, COVID-19, and coronary artery disease: killing two birds with one stone
  67. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors
  68. Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go
  69. Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes
  70. Comparison of LDL-C calculation by friedewald and martin/hopkins methods in 12,243 adults from the United States of America
  71. LDL-C: lower is better for longer—even at low risk
  72. Pharmacist implementation of a treatment pathway for atrial fibrillation in care home residents
  73. The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
  74. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
  75. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
  76. Epigenetic control of atherosclerosis via DNA methylation: A new therapeutic target?
  77. Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice
  78. What's new in lipid‐lowering pharmacology? Integrating basic and clinical research to improve patient outcomes
  79. Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP)
  80. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
  81. The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP)
  82. Liposome Circulation Time is Prolonged by CD47 Coating
  83. Intake of Caffeine and Its Association with Physical and Mental Health Status among University Students in Bahrain
  84. Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants
  85. Application of PLGA nano/microparticle delivery systems for immunomodulation and prevention of allotransplant rejection
  86. Vitamin D and SAMS
  87. Inclisiran—New hope in the management of lipid disorders?
  88. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications
  89. Statins and Lp(a): do not make perfect the enemy of excellent
  90. The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis
  91. P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel
  92. Warfarin Therapy and Improved Anticoagulation Control by Patient Self-Management
  93. A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome
  94. Regulatory T cells: possible mediators for the anti-inflammatory action of statins
  95. Genetic testing in familial hypercholesterolaemia: What does it add?
  96. Poster Abstracts
  97. Worldwide Dyslipidemia Guidelines
  98. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?
  99. Associations between the lipid profile and the development of hypertension in young individuals – the preliminary study
  100. Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis
  101. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
  102. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
  103. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
  104. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study
  105. P3836The prognostic accuracy of bleeding risk prediction scores in patients with atrial fibrillation: a systematic review and meta-analysis
  106. P5086Associations between very low concentrations of LDL-Cholesterol, hsCRP and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
  107. Lipoprotein(a) and the risk of atrial fibrillation – is there a link
  108. The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis
  109. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis
  110. Autonomic and Autacoid Pharmacology: Goodbye and thank you
  111. Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review
  112. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials
  113. 3100Effects of morning versus evening statin therapy on lipid profile: a systematic review and meta-analysis
  114. 3104Associations between cardiovascular disease, cancer and very low hdl cholesterol in the reasons for geographical and racial differences in stroke (REGARDS) study
  115. P627Associations between very low concentrations of LDL-cholesterol and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) Study
  116. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis
  117. The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis
  118. 220 Daphnia magna as a model for quantifying chaos in cardiac arrhythmia
  119. Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease
  120. The role of nutraceuticals in the prevention of cardiovascular disease
  121. Evaluating bempedoic acid for the treatment of hyperlipidaemia
  122. Association between telomere length and complete blood count in US adults
  123. D-003 (Saccharum officinarum): The forgotten lipid-lowering agent
  124. Effects of pentoxifylline on inflammatory markers and blood pressure
  125. Sunday 28 August 2016
  126. Monday 29 August 2016
  127. Tuesday 30 August 2016
  128. Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease?
  129. Autonomic & Autacoid Pharmacology 2016: The year in review
  130. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – Some answers and still many questions
  131. Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials
  132. Autonomic & Autacoid Pharmacology: past, present and future
  133. Developing skills to deliver alcohol screening and brief intervention (SBI) in community pharmacy
  134. Lecturing: A lost art
  135. ChemInform Abstract: Synthesis of Antagonists of Muscarinic (M3) Receptors.
  136. Synthesis of antagonists of muscarinic (M3) receptors
  137. Incense – A problematic method of drug-delivery
  138. Activation of β-adrenoceptors mimics preconditioning of rat-isolated atria and ventricles against ischaemic contractile dysfunction
  139. Protective role of β2- and β3-adrenoceptors at reperfusion in isolated rat heart
  140. Vasopressors for cardiopulmonary resuscitation
  141. Effects of hypoxia on the vasodilator activity of nifedipine and evidence of secondary pharmacological properties
  142. The roles of alpha- and beta-adrenoceptor stimulation in myocardial ischaemia